Literature DB >> 15844073

High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania.

Lillian Mtei1, Mecky Matee, Oliver Herfort, Muhammad Bakari, C Robert Horsburgh, Richard Waddell, Bernard F Cole, Jenni M Vuola, Susan Tvaroha, Barry Kreiswirth, Kisali Pallangyo, C Fordham von Reyn.   

Abstract

BACKGROUND: We sought to determine the prevalence of active tuberculosis among ambulatory HIV-infected persons in Tanzania with CD4 cell counts of > or =200 cells/mm3 and a bacille Calmette-Guerin vaccination scar.
METHODS: Subjects who volunteered for a tuberculosis booster vaccine trial were screened for active tuberculosis by obtainment of a history, physical examination, chest radiography, sputum culture and acid fast bacillus (AFB) stain, and blood culture. All subjects underwent a tuberculin skin test (TST) and lymphocyte proliferation assays (LPAs) for detection of responses to mycobacterial antigens.
RESULTS: Active tuberculosis was identified at baseline in 14 (15%) of the first 93 subjects who were enrolled: 10 (71%) had clinical tuberculosis (symptoms or chest radiograph findings), and 4 (29%) had subclinical tuberculosis (positive sputum AFB stain or culture results but no symptoms or chest radiograph findings). An additional 6 subjects with subclinical tuberculosis were identified subsequently. The 10 subjects with subclinical tuberculosis included 3 with positive sputum AFB stains results and 7 who were only identified by a positive sputum culture result. Compared with subjects who did not have tuberculosis, the 10 subjects with subclinical tuberculosis were more likely to have peripheral lymphadenopathy, positive TST results, and elevated LPA responses to early secreted antigenic target-6 (ESAT). Eight of 10 patients had received isoniazid because of a positive TST result before active tuberculosis was recognized.
CONCLUSIONS: Clinical and subclinical tuberculosis are common among ambulatory HIV-infected persons, and some cases can only be identified by sputum culture. World Health Organization guidelines for screening for latent tuberculosis before treatment do not recommend sputum culture and, therefore, may fail to identify a substantial number of HIV-infected persons with subclinical, active tuberculosis.

Entities:  

Mesh:

Year:  2005        PMID: 15844073     DOI: 10.1086/429825

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  72 in total

1.  Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies.

Authors:  Annelies Van Rie; Daniel Westreich; Ian Sanne
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

2.  Performance of nucleic acid amplification following extraction of 5 milliliters of whole blood for diagnosis of Mycobacterium tuberculosis bacteremia.

Authors:  John A Crump; Marion J Tuohy; Anne B Morrissey; Habib O Ramadhani; Boniface N Njau; Venance P Maro; L Barth Reller; Gary W Procop
Journal:  J Clin Microbiol       Date:  2011-10-26       Impact factor: 5.948

3.  CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques.

Authors:  Philana Ling Lin; Tara Rutledge; Angela M Green; Matthew Bigbee; Carl Fuhrman; Edwin Klein; JoAnne L Flynn
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-04       Impact factor: 2.205

4.  Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis.

Authors:  Timothy Lahey; Siddharth Sheth; Mecky Matee; Robert Arbeit; C Robert Horsburgh; Lillian Mtei; Todd Mackenzie; Muhammad Bakari; Jenni M Vuola; Kisali Pallangyo; C Fordham von Reyn
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

5.  Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control.

Authors:  Robin Wood; Keren Middelkoop; Landon Myer; Alison D Grant; Andrew Whitelaw; Stephen D Lawn; Gilla Kaplan; Robin Huebner; James McIntyre; Linda-Gail Bekker
Journal:  Am J Respir Crit Care Med       Date:  2006-09-14       Impact factor: 21.405

6.  Epidemiology of smear - negative tuberculosis in ibadan, Nigeria.

Authors:  Oludiran Kehinde Aderemi; Hannah Dada-Adegbola
Journal:  Afr J Infect Dis       Date:  2013

7.  Optimal treatment of Codisease due to HIV and tuberculosis.

Authors:  C Fordham von Reyn
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

Review 8.  Latent tuberculosis: what the host "sees"?

Authors:  Hannah P Gideon; JoAnne L Flynn
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

9.  Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV.

Authors:  R Dawson; P Masuka; D J Edwards; E D Bateman; L-G Bekker; R Wood; S D Lawn
Journal:  Int J Tuberc Lung Dis       Date:  2010-01       Impact factor: 2.373

10.  Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis.

Authors:  Timothy Lahey; Mecky Matee; Lillian Mtei; Muhammad Bakari; Kisali Pallangyo; C Fordham von Reyn
Journal:  BMC Infect Dis       Date:  2009-02-23       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.